natgillin/translations-raw huggingface dataset:
Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors. 
Aflibercept deluje kot topen vabni receptor, ki veže VEGF-A in PlGF z večjo afiniteto kot njihovi naravni receptorji, zato lahko zavira vezavo in aktivacijo sorodnih receptorjev VEGF.
Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including those with Eylea (see section 4.8). 
Povišanje intraokularnega tlaka so opažali v 60 minutah po intravitrealni injekciji, tudi po injiciranju zdravila Eylea (glejte poglavje 4.8).
Eylea has been shown to stop the growth of new abnormal blood vessels in the eye which often leak fluid or bleed. 
Dokazano je, da zdravilo Eylea ustavi rast novih nenormalnih krvnih žil v očesu, iz katerih pogosto izteka tekočina ali kri.
Note: Filter needle is not to be used for intravitreal injection. 
Opozorilo: Filtrirne igle ne uporabite za intravitrealno injiciranje.
Results from animal studies with high systemic exposure indicate that aflibercept can impair male and female fertility (see section 5.3). 
Izsledki študij na živalih, pri katerih je bila sistemska izpostavljenost velika, kažejo, da ima lahko aflibercept škodljiv vpliv na plodnost pri moških in ženskah (glejte poglavje 5.3).
The systemic use of VEGF inhibitors, substances similar to those contained in Eylea, is potentially related to the risk of blood clots blocking blood vessels (arterial thromboembolic events) which may lead to heart attack or stroke. 
Sistemska uporaba zaviralcev VEGF, snovi, podobnih tistim, ki jih vsebuje zdravilo Eylea, je lahko povezana s tveganjem za nastanek krvnih strdkov, ki zamašijo krvne žile (arterijski trombembolični dogodki), kar lahko privede do srčnega napada ali možganske kapi.
Patients should be instructed to report any signs or symptoms of intraocular inflammation, e.g. pain, photophobia, or redness, which may be a clinical sign attributable to hypersensitivity. 
Bolnike je treba poučiti, da poročajo o vseh znakih in simptomih vnetja v očesu npr. bolečini, fotofobiji ali pordelosti, ki bi lahko bili klinični znaki preobčutljivosti.
VEGF acts via two receptor tyrosine kinases; VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. 
VEGF deluje preko dveh tirozinkinaznih receptorjev, VEGFR-1 in VEGFR-2, ki sta prisotna na površini endotelijskih celic.
Free aflibercept binds VEGF to form a stable, inert complex. 
Prosti aflibercept se z VEGF veže v stabilni inertni kompleks.
(97.5% CI) 
(97,5 % IZ)
- Eylea is not recommended during breast-feeding as it is not known whether Eylea passes into human milk. 
- Uporaba zdravila Eylea se ne priporoča med dojenjem, saj ni znano, ali zdravilo Eylea prehaja v materino mleko.
Myopic choroidal neovascularisation (myopic CNV) is a frequent cause of vision loss in adults with pathologic myopia. 
Miopična horoidalna neovaskularizacija (miopična CNV) je pogost vzrok izgube vida pri odraslih s patološko kratkovidnostjo.
The most frequently observed adverse reactions (in at least 5% of patients treated with Eylea) were conjunctival haemorrhage (25%), visual acuity reduced (11%), eye pain (10%), cataract (8%), intraocular pressure increased (8%), vitreous detachment (7%), and vitreous floaters (7%). 
Najpogosteje opaženi neželeni učinki (pri vsaj 5 % bolnikov, zdravljenih z zdravilom Eylea) so bili krvavitev pod očesno veznico (25 %), zmanjšana ostrina vida (11 %), bolečina v očesu (10 %), katarakta (8 %), povišan intraokularni tlak (8 %), odstop steklovine (7 %) in motnjave v steklovini
This decrease from baseline in CRT was maintained to the end of each study, week 100 in COPERNICUS, week 76 in GALILEO, and week 52 in VIBRANT. 
Zmanjšanje CRT glede na izhodiščne vrednosti se je ohranilo do konca vsake študije, do 100. tedna v študiji COPERNICUS, 76. tedna v študiji GALILEO in 52. tedna v študiji VIBRANT.
• Female patients of childbearing potential have to use effective contraception and pregnant women should not use Eylea 
• bolnice v rodni dobi morajo uporabljati učinkovito kontracepcijo, pri nosečnicah pa se zdravila ne sme uporabljati
In the VIVIDDME and VISTADME studies, 36 (9%) and 197 (43%) patients received prior anti-VEGF therapy, respectively, with a 3-month or longer washout period. 
V študijah VIVIDDME in VISTADME je 36 (9 %) oziroma 197 (43 %) bolnikov prejemalo predhodno zdravljenje z zaviralci VEGF s 3-mesečnim ali daljšim obdobjem izpiranja.
As with other intravitreal anti-VEGF treatments for AMD, CRVO, BRVO, DME and myopic CNV the following also applies: 
Kot pri drugih intravitrealnih zaviralcih VEGF za zdravljenje AMD, CRVO, BRVO, DME in miopične CNV je treba upoštevati tudi naslednje:
The beneficial effect of Eylea treatment on visual function was similar in the baseline subgroups of perfused and non-perfused patients. 
Koristni učinki zdravljenja z zdravilom Eylea na vid so bili na začetku podobni v podskupinah perfundiranih in neperfundiranih bolnikov.
If any of these apply to you, Eylea will be given with caution. 
Če se kar koli od naštetega nanaša na vas, vam bodo dajali zdravilo Eylea posebno previdno.
DifferenceC) (95% CI)D) 
RazlikaC (95 % IZ)D
What Eylea contains - The active substance is: aflibercept. 
Kaj vsebuje zdravilo Eylea - Učinkovina je aflibercept.
What you need to know before you are given Eylea 
Kaj morate vedeti, preden boste prejeli zdravilo Eylea
The schedule for monitoring should be determined by the treating physician. 
Načrt spremljanja bolnika mora določiti lečeči zdravnik.
- your doctor will check whether you have other risk factors that may increase the chance of a tear or detachment of one of the layers at the back of the eye (retinal detachment or tear, and retinal pigment epithelial detachment or tear), in which case Eylea must be given with caution. 
- Zdravnik bo preveril ali pri vas obstajajo drugi dejavniki tveganja, kar lahko poveča možnost za raztrganine ali odstop ene od plasti v zadnjem delu očesa (odstop ali raztrganine mrežnice, in odstop ali zatrganje pigmentnega epitelija mrežnice), ker je treba v teh primerih dati zdravilo Eylea posebno previdno.
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells. 
Žilni endotelijski rastni dejavnik-A (VEGF-A) in placentni rastni dejavnik (PlGF) spadata v skupino VEGF angiogenih dejavnikov, ki lahko delujejo kot močni dejavniki mitogene, kemotaktične in žilne prepustnosti za endotelijske celice.
Effects on male and female fertility were assessed as part of a 6-month study in monkeys with intravenous administration of aflibercept at doses ranging from 3 to 30 mg/kg. 
Učinke na sposobnost razmnoževanja pri moških in ženskah so ocenili kot del 6-mesečne študije pri opicah, ki so jim intravensko aplicirali aflibercept v odmerkih od 3 do 30 mg/kg.
• Do not use this medicine after the expiry date which is stated on the carton and label after EXP. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
• Patient monitoring after intravitreal injection including monitoring for visual acuity and increase of intraocular pressure post-injection 
• spremljanje bolnikov po prejemu intravitrealne injekcije vključno s spremljanjem ostrine vida in povišanja intraokularnega tlaka po injiciranju
In the second year of the studies, efficacy was generally maintained through the last assessment at week 96, and 2-4% of patients required all injections on a monthly basis, and a third of patients required at least one injection with a treatment interval of only one month. 
V drugem letu študij se je učinkovitost v splošnem ohranila do zadnjega ocenjevanja v 96. tednu; pri 2 - 4 % bolnikov so bile potrebne vse injekcije v intervalu enega meseca; pri tretjini bolnikov pa je bila po enem mesecu potrebna vsaj ena injekcija.
Effects in non-clinical studies on repeated dose toxicity were observed only at systemic exposures considered substantially in excess of the maximum human exposure after intravitreal administration at the intended clinical dose indicating little relevance to clinical use. 
V predkliničnih študijah so učinke toksičnosti pri ponavljajočih odmerkih opazili samo pri sistemskih izpostavljenostih, ki so močno presegale največjo izpostavljenost pri ljudeh po intravitrealni aplikaciji izbranega kliničnega odmerka, kar kaže na majhen pomen za klinično uporabo.
Intravitreal injections must be carried out according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. 
Intravitrealne injekcije mora v skladu s strokovnimi standardi in veljavnimi smernicami aplicirati usposobljen zdravnik, ki ima izkušnje z dajanjem intravitrealnih injekcij.
Pharmacokinetic analysis of patients in the VIEW2 study, of which 40% had renal impairment (24% mild, 15% moderate, and 1% severe), revealed no differences with respect to plasma concentrations of active drug after intravitreal administration every 4 or 8 weeks. 
Farmakokinetične analize bolnikov v študiji VIEW2, v kateri je imelo 40 % bolnikov ledvično okvaro (24 % blago, 15 % zmerno in 1 % hudo), po intravitrealni aplikaciji vsake 4 ali vsakih 8 tednov, niso pokazale razlik v koncentracijah učinkovine v plazmi.
Similar results were seen in patients with CRVO in the GALILEO study, in patients with DME in the VIVIDDME study, and in patients with myopic CNV in the MYRROR study. 
Podobne izsledke so opazili pri bolnikih s CRVO v študiji GALILEO, bolnikih z DME v študiji VIVIDDME in bolnikih z miopično CNV v študiji MYRROR.
Final study report submission: 30 
predložitev končnega poročila o študiji: 30. november
Ensure that the plunger rod is drawn sufficiently back when emptying the vial in order to completely empty the filter needle. 
Prepričajte se, da je med praznjenjem viale bat potegnjen dovolj nazaj, da filtrirno iglo povsem izpraznite.
Elimination As Eylea is a protein-based therapeutic, no metabolism studies have been conducted. 
Izločanje Ker je zdravilo Eylea terapevtski protein, študij presnove niso izvedli.
Eylea has not been studied in patients with active systemic infections or in patients with concurrent eye conditions such as retinal detachment or macular hole. 
Zdravila Eylea niso preučevali pri bolnikih z aktivno sistemsko okužbo ali pri bolnikih s sočasnimi očesnimi boleznimi, kot sta odstop mrežnice ali makularna luknja.
In both studies Eylea was shown to be non-inferior and clinically equivalent to the ranibizumab 0.5Q4 group. 
V obeh študijah se je pokazalo, da je zdravljenje z zdravilom Eylea neinferiorno in klinično enakovredno zdravljenju z ranibizumabom 0,5Q4.
If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top. 
Če so mehurčki, s prsti nežno potrkajte po brizgi, da se mehurčki dvignejo na vrh brizge.
100 Weeks 
100 tednov
- injections with Eylea may cause an increase in eye pressure (intraocular pressure) in some patients within 60 minutes of the injection. 
- Injiciranje zdravila Eylea lahko pri nekaterih bolnikih v 60 minutah po injiciranju povzroči povišanje očesnega tlaka (intraokularni tlak).
To avoid compromising the sterility of the product, do not pull back on the plunger. 
Za zagotovitev sterilnosti zdravila, bata ne vlecite nazaj.
Therefore, in case of overdose, intraocular pressure should be monitored and if deemed necessary by the treating physician, adequate treatment should be initiated. 
V primeru prevelikega odmerjanja je treba spremljati intraokularni tlak in uvesti ustrezno zdravljenje, če lečeči zdravnik oceni, da je potrebno.
What Eylea is and what it is used for What you need to know before you are given Eylea How you will be given Eylea Possible side effects 
Kaj je zdravilo Eylea in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Eylea Kako boste prejeli zdravilo Eylea Možni neželeni učinki
It is unknown whether aflibercept is excreted in human milk. 
Dojenje Ni znano, ali se aflibercept izloča v materino mleko.
Three or more consecutive, monthly injections may be needed. 
Morda bo tri ali več zaporednih mesecev potrebna 1 injekcija na mesec.
Your doctor may decide to stop treatment with Eylea if it is determined that you are not benefiting from continued treatment. 
Zdravnik se lahko odloči za prenehanje zdravljenja z zdravilom Eylea, če bo ugotovil, da vam nadaljnje zdravljenje ne bi koristilo.
If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, Eylea should be discontinued. 
Če ocena ostrine vida in anatomski izgled rumene pege kažeta, da bolnik nima koristi od nadaljevanja zdravljenja, je treba zdravljenje z zdravilom Eylea prenehati.
Beginning at week 24, patients meeting a pre-specified threshold of vision loss were eligible to receive additional treatment: patients in the Eylea groups could receive laser and patients in the control group could receive Eylea. 
V 24. tednu so začeli bolniki, ki so dosegli vnaprej določen prag izgube vida, prejemati dodatno zdravljenje: bolniki v skupini, ki je prejemala zdravilo Eylea, so se lahko zdravili lasersko in bolniki v kontrolni skupini so lahko prejeli zdravilo Eylea.
Extension or shortening of the treatment interval was decided based on visual and/or anatomic criteria defined by protocol with a maximum treatment interval of 16 weeks for both groups. 
Podaljšanje ali skrajšanje intervala med injekcijami je bilo določeno glede na oceno ostrine vida in/ali anatomski izgled rumene pege, določenem po protokolu; največji interval med injekcijami je bil 16 tednov za obe skupini.
Overdosing with increased injection volume may increase intraocular pressure. 
Prekomerno odmerjanje z injiciranjem večje količine raztopine lahko poviša intraokularni tlak.
Clinical efficacy and safety wet AMD 
Klinična učinkovitost in varnost
- There is no experience of using Eylea in pregnant women. 
- Izkušenj z uporabo zdravila Eylea pri nosečnicah ni.
What Eylea looks like and contents of the pack 
Izgled zdravila Eylea in vsebina pakiranja
Ranibizumab 0.5Q4 (ranibizumab 0.5 mg every 4 weeks) 
ranibizumab 0,5Q4 (ranibizumab 0,5 mg vsake 4 tedne)
There is limited experience in patients older than 75 years with DME. 
Izkušnje pri bolnikih z diabetičnim makularnim edemom, starejših od 75 let, so omejene.
In the laser group 67 patients received rescue treatment with Eylea beginning at week 24 (Active Control/ Eylea 2mg group), which resulted in improvement of visual acuity by about 5 letters from week 24 to 52. 
V kontrolni skupini z laserskim zdravljenjem je 67 bolnikov v začetku 24. tedna prejelo rešilno zdravljenje z zdravilom Eylea (aktivna kontrola/zdravilo Eylea 2 mg), kar se je kazalo v izboljšanju ostrine vida za 5 črk od 24. do 52. tedna.
At week 24, the reduction in CRT was statistically superior versus control in all three studies (COPERNICUS in CRVO: -457 vs. -145 microns; GALILEO in CRVO: -449 vs. -169 microns; VIBRANT in BRVO:280 vs. -128 microns). 
V 24. tednu je bilo zmanjšanje CRT superiorno v primerjavi s kontrolno skupino v vseh treh študijah (COPERNICUS pri CRVO: -457 oziroma -145 mikronov; GALILEO pri CRVO: -449 oziroma -169 mikronov; VIBRANT pri BRVO: -280 oziroma -128 mikronov).
There is only limited experience in the treatment of subjects with DME due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy. 
Izkušnje z zdravljenjem bolnikov z diabetičnim makularnim edemom zaradi sladkorne bolezni tipa I ali bolnikov s sladkorno boleznijo, pri katerih je HbA1c več kot 12 % ali s proliferativno diabetično retinopatijo, so omejene.
Thereafter, plasma concentrations of free aflibercept declined to values below or close to the lower limit of quantitation generally within one week; undetectable concentrations were reached before the next administration after 4 weeks in all patients. 
Plazemske koncentracije prostega aflibercepta so se znižale do vrednosti pod ali blizu spodnje meje običajno v enem tednu; pred naslednjim injiciranjem po 4 tednih so bile koncentracije pri vseh bolnikih nezaznavne.
The European Medicines Agency has waived the obligation to submit the results of studies with Eylea in all subsets of the paediatric population in wet AMD, CRVO, BRVO, DME and myopic CNV populations (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Eylea za vse podskupine pediatrične populacije z vlažno AMD, CRVO, BRVO, DME in miopično CNV (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
In patients treated with 6 consecutive monthly injections of Eylea 2mg, there was a consistent, rapid and robust morphologic response (as measured by improvements in mean CRT) observed. 
Pri bolnikih, zdravljenih s 6 zaporednimi mesečnimi injekcijami zdravila Eylea 2 mg je bil opažen dosleden, hiter in robusten morfološki odgovor (na podlagi meritev izboljšanj povprečne CRT).
Aflibercept, the active substance in Eylea, blocks the activity of a group of factors, known as Vascular Endothelial Growth Factor A (VEGF-A) and Placental Growth Factor (PlGF). 
Aflibercept, učinkovina v zdravilu Eylea, zavira delovanje skupine dejavnikov, znanih kot VEGF-A (žilni endotelijski rastni dejavnik A) in PlGF (placentni rastni dejavnik).
In addition, patients should be monitored during the week following the injection to permit early treatment if an infection occurs. 
V tednu po prejemu injekcije je treba bolnike dodatno spremljati, da se, v primeru okužbe, lahko začne zgodnje zdravljenje.
Leakage of blood and fluid from CNV may cause retinal thickening or oedema and/or sub-/intra-retinal haemorrhage, resulting in loss of visual acuity. 
Iztekanje krvi in tekočin iz CNV lahko povzroči zadebelitev ali edem mrežnice in/ali sub-/intraretinalno krvavitev ter posledično izgubo ostrine vida.
The adverse reactions are listed by system organ class and frequency using the following convention: 
Neželeni učinki so navedeni po organskih sistemih in pogostnosti kot sledi:
Bayer AG Müllerstraße 178 13353 Berlin Germany 
Bayer AG Müllerstraße 178 13353 Berlin Nemčija
In the wet AMD phase III studies, there was an increased incidence of conjunctival haemorrhage in patients receiving anti-thrombotic agents. 
V študijah III. faze pri bolnikih z vlažno AMD je bila povečana incidenca krvavitev pod očesno veznico pri bolnikih, ki so prejemali antitrombotike.
• The need to expel excess volume of the syringe before injecting Eylea to avoid overdose 
• iztis odvečnega volumna iz injekcijske brizge pred injiciranjem zdravila Eylea v izogib prevelikemu odmerjanju
- if you develop an infection or inflammation inside the eye (endophthalmitis) or other complications, you may have eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, and increased sensitivity to light. 
- Če imate okužbo ali vnetje v očesu (endoftalmitis) ali druge zaplete, se vam lahko pojavijo bolečine v očesu ali poslabša neprijeten občutek v očesu, poveča pordelost očesa, pojavi zamegljen vid ali poslabša ostrina vida in poveča občutljivost za svetlobo.
When ready to administer Eylea, open the carton and remove the sterilized blister. 
Ko ste pripravljeni za aplikacijo zdravila Eylea, odprite škatlo in odstranite steriliziran pretisni omot.
Diabetic macular oedema is a consequence of diabetic retinopathy and is characterised by increased vasopermeability and damage to the retinal capillaries which may result in loss of visual acuity. 
Diabetični makularni edem je posledica diabetične retinopatije in zanj sta značilna povečana žilna prepustnost in poškodbe mrežničnih kapilar, kar lahko povzroči izgubo ostrine vida.
In the laser group, where patients were eligible for rescue treatment with Eylea from week 24, the proportion of perfused patients increased to 78% by week 52. 
V kontrolni skupini z laserskim zdravljenjem, kjer so bili od 24. tedna bolniki primerni za rešilno zdravljenje z zdravilom Eylea, se je delež perfundiranih bolnikov do 52. tedna povečal na 78 %.
• Eylea should not be used in pregnancy unless the potential benefit outweighs the potential risk to the foetus (see section 4.6). 
• Zdravila Eylea se ne sme uporabljati med nosečnostjo, razen če so možne koristi večje od možnega tveganja za plod (glejte poglavje 4.6).
There is only limited experience in the treatment of - patients with DME due to type I diabetes. 
Izkušnje so omejene pri zdravljenju - bolnikov z DME zaradi sladkorne bolezni tipa I,
Wet AMD is characterised by pathological choroidal neovascularisation (CNV). 
Za vlažno AMD je značilna patološka horoidalna neovaskularizacija (CNV).
• The dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of: o a decrease in best-corrected visual acuity (BCVA) of ≥30 letters compared with the last assessment of visual acuity; o a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is ≥50%, of the total lesion area. 
• Z zdravljenjem je treba prenehati in se ga ne sme ponovno začeti prej kot ob naslednjem načrtovanem odmerku v naslednjih primerih: zmanjšana najboljša korigirana ostrina vida (BCVA) > 30 črk v primerjavi z zadnjo oceno ostrine vida, krvavitev pod mrežnico, tudi v vidni jamici (fovea centralis), ali če je velikost krvavitve > 50 % celotne lezije.
It develops as a wound healing mechanism consequent to Bruch's membrane ruptures and represents the most vision-threatening event in pathologic myopia. 
Razvije se kot mehanizem za celjenje ran, ki so posledice ruptur Bruchove membrane in najbolj ogrožajo vid pri patološki kratkovidnosti.
MARKETING AUTHORISATION NUMBER(S) EU/1/12/797/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/12/797/001
In the clinical trials, there was an increased incidence of bleeding from small blood vessels in the outer layers of the eye (conjunctival haemorrhage) in patients with wet AMD receiving blood thinners. 
V kliničnih preskušanjih je bila povečana pogostnost krvavitve iz manjših krvnih žil v zunanje plasti očesa (krvavitev pod veznico) pri bolnikih z vlažno starostno degeneracijo makule, ki so prejemali zdravila za redčenje krvi.
An effect of aflibercept on intrauterine development was shown in embryo-foetal development studies in pregnant rabbits with intravenous (3 to 60 mg/kg) as well as subcutaneous (0.1 to 1 mg/kg) administration. 
Učinek aflibercepta na intrauterini razvoj se je pokazal v študiji razvoja zarodka/ploda pri brejih kunčjih samicah po intravenski (3 do 60 mg/kg) in po subkutani uporabi (0,1 do 1 mg/kg).
As this is a therapeutic protein, there is a potential for immunogenicity with Eylea (see section 4.8). 
Ker je aflibercept terapevtski protein, obstaja možnost za imunogenost zdravila Eylea (glejte poglavje 4.8).
The maximal improvement in visual acuity was achieved at month 3 with subsequent stabilisation of visual acuity and CRT until month 6. 
V obeh ključnih študijah je bilo največje izboljšanje ostrine vida doseženo v tretjem mesecu, ki mu je sledila stabilizacija ostrine vida in CRT do šestega meseca.
There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. 
Teoretično obstaja tveganje za arterijske trombembolične dogodke, tudi možgansko kap in miokardni infarkt, po intravitrealni uporabi zaviralcev VEGF.
Active Control (laser) 
aktivna kontrola (lasersko zdravljenje
A total of 121 patients were treated and evaluable for efficacy (90 with Eylea). 
Zdravili so skupno 121 bolnikov in pri njih je bila ocenjena učinkovitost (90 bolnikov je bilo zdravljenih z zdravilom Eylea).
As with all therapeutic proteins, there is a possibility for an immune reaction (formation of antibodies) with Eylea. 
Kot pri vseh terapevtskih beljakovinah obstaja možnost imunske reakcije (nastanka protiteles) z zdravilom Eylea.
Eylea is for intravitreal injection only. 
Zdravilo Eylea je samo za intravitrealno injiciranje.